Idiosyncratic drug hepatotoxicity
The DOI matches its Crossref record; 154 of the 155 references it cites were found in a registry or an index.
Abstract
The occurrence of idiosyncratic drug hepatotoxicity is a major problem in all phases of clinical drug development and the most frequent cause of post-marketing warnings and withdrawals. This review examines the clinical signatures of this problem, signals predictive of its occurrence (particularly of more frequent, reversible, low-grade injury) and the role of monitoring in prevention by examining several recent examples (for example, troglitazone). In addition, the failure of preclinical toxicology to predict idiosyncratic reactions, and what can be done to improve this problem, is discussed. Finally, our current understanding of the pathophysiology of experimental drug hepatotoxicity is examined, focusing on acetaminophen, particularly with respect to the role of the innate immune system and control of cell-death pathways, which might provide targets for exploration and identification of risk factors and mechanisms in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current drug development process suffers from a high failure rate during clinical trials, which is partly due to inadequacy of animal models to accurately predict the toxic side-effects of drugs in humans [1,2].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [2]
In the citing paper
“Drug-induced liver injury (DILI) is a common adverse drug reaction (ADR), and it can lead to liver failure and even death.[1][2][3]”
From Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (2019) · cites this paper as [1]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Acetaminophen-induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136547 · Cited by 1,092
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Research works printed but not linked: 3
- Nelson, S. D. & Bruschi, S. A. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 287–325 (Marcel Dekker, New York, 2003).
- Chien, J. Y., Thummel, K. E. & Slattery, J. T. Pharmakinetic consequence of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 25, 1165–1175 (1997).
- Liu, Z. -X. & Kaplowitz, N. in Clinics in Liver Disease 6, 467–486 (Elsevier, 2002).
Cited by
Items 601–700 of 999
Pannala, V. R., Vinnakota, K. C., Estes, S. K., Trenary, I. A., O’Brien, T. P., Printz, R. L., Papin, J. A., Reifman, J., Oyama, T., Shiota, M., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz228 · Cited by 12
Acetaminophen-induced acute liver injury in HCV transgenic mice
Uehara, T., Kosyk, O., Jeannot, E., Bradford, B. U., Tech, K., Macdonald, J. M., Boorman, G. A., Chatterjee, S., Mason, R. P., Melnyk, S. B., et al. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.11.019 · Cited by 14
Lucena, M. I., Cohen, H., Hernández, N., Bessone, F., Dacoll, C., Stephens, C. M., Borraz, Y., Ulzurrun, E., Bruguera, M., & Andrade, R. J. (2011) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2011.01.003 · Cited by 13
Anadón, A., Castellano, V., & Martínez-Larrañaga, M. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00034-8 · Cited by 16
Takemura, A., Gong, S., Sato, T., Kawaguchi, M., Sekine, S., Kazuki, Y., Horie, T., & Ito, K. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.06.001 · Cited by 13
Tricyclic antidepressants induce liver inflammation by targeting NLRP3 inflammasome activation
Mu, W., Xu, G., Wang, Z., Li, Q., Sun, S., Qin, Q., Li, Z., Shi, W., Dai, W., Zhan, X., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01128-x · Cited by 15
Cosgrove, B. D., Alexopoulos, L. G., Sáez-Rodríguez, J., Griffith, L. G., & Lauffenburger, D. A. (2009) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2009.5334019 · Cited by 16
Drug induced liver injury:a review
Kosanam, S., Boyina, R., & Lakshmi Prasanthi, N. (2015) · International Journal of Pharmacological Research · doi:10.7439/ijpr.v5i2.1507 · Cited by 13
Jemnitz, K., Bátai-Konczos, A., Szabó, M., Ioja, E., Kolacsek, O., Orbán, T. I., Török, G., Homolya, L., Kovács, E., Jablonkai, I., et al. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.09.016 · Cited by 17
Epidemiology and Risk Factors for Severe Delayed Drug Hypersensitivity Reactions
Gomes, E. R., Marques, M. L., & Regateiro, F. S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191105115346 · Cited by 16
Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury
Krueger, W. H., Boelsterli, U. A., & Rasmussen, T. P. (2014) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00012 · Cited by 14
Fujimoto, K., Kishino, H., Yamoto, T., Manabe, S., & Sanbuissho, A. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.012 · Cited by 13
Grieco, A., Miele, L., Forgione, A., Ragazzoni∘, E., Vecchio, F. M., & Gasbarrini, G. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00918.x · Cited by 13
Liu, F., Li, Y., Zhu, J., Li, Y., Zhu, D., Luo, J., & Kong, L. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106899 · Cited by 13
Yang, H., Park, T., Park, D., & Kang, M.-G. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105374 · Cited by 12
Tang, M. H. Y., Helsby, N. A., Goldthorpe, M. A., Thompson, K. M., Al-Ali, S., & Tingle, M. D. (2007) · Toxicology · doi:10.1016/j.tox.2007.07.018 · Cited by 12
Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort
Shantakumar, S., Landis, S., Lawton, A., & Hunt, C. M. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.03.019 · Cited by 12
Risk Factors for Drug-Induced Liver Disease
Vuppalanchi, R., & Chalasani, N. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00016-9 · Cited by 12
The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice
Dickie, A. P., Wilson, C. E., Schreiter, K., Wehr, R., Wilson, E. M., Bial, J., Scheer, N., Wilson, I. D., & Riley, R. J. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.015 · Cited by 13
Cheng, W., Li, Y., Yang, W. Q., Wu, S., Wei, M., Gao, Y., Chen, K., Zhang, S., & Li, Y. (2020) · International Journal of Analytical Chemistry · doi:10.1155/2020/4508374 · Cited by 12
Pietrangelo, A., Elferink, R. P. J. O., Prìeto, J., & Bacon, B. R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.03.009 · Cited by 12
“Omics” Technologies and the Immune System
Burns‐Naas, L. A., Dearman, R. J., Germolec, D. R., Kaminski, N. E., Kimber, I., Ladics, G. S., Luebke, R. W., Pfau, J. C., & Pruett, S. B. (2006) · Toxicology Mechanisms and Methods · doi:10.1080/15376520600558424 · Cited by 13
Tonomura, Y., Kato, Y., Hanafusa, H., Morikawa, Y., Matsuyama, K., Uehara, T., Ueno, M., & Torii, M. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.3053 · Cited by 12
Chou, J. W., & Bushel, P. R. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-272 · Cited by 13
Goto, S., Seo, T., Hagiwara, T., Ueda, K., Yamauchi, T., Nagata, S., Ando, Y., Ishitsu, T., & Nakagawa, K. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.2.0017 · Cited by 12
Mechanisms of Drug‐Induced Liver Injury
Watkins, P. B. (2011) · Wiley eBooks · doi:10.1002/9781119950509.ch28 · Cited by 12
The promise of organotypic hepatic and gastrointestinal models
Vu, L. T., Less, R. R., & Rajagopalan, P. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.04.006 · Cited by 12
Xu, J., Xiong, A., Wang, X., Yan, X., Chen, Y., Ye, X., Wang, Z., Ding, L., & Yang, L. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01460-3 · Cited by 13
Tian, J., Zhang, S., Li, L., Lin, X., Li, Y., Zhao, K., Zheng, F., Chen, Y., Yang, Y., Wu, T., et al. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231211862 · Cited by 12
Using microRNA as Biomarkers of Drug-Induced Liver Injury
Salminen, W. F., Yang, X., & Shi, Q. (2011) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000119 · Cited by 11
Biomarkers for drug-induced liver injury
Watkins, P. B. (2010) · Therapy · doi:10.2217/thy.10.10 · Cited by 12
Selective voting in convex-hull ensembles improves classification accuracy
Kodell, R. L., Zhang, C., Siegel, E. R., & Nagarajan, R. (2011) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2011.10.003 · Cited by 12
Kakisaka, K., Kataoka, K., Suzuki, Y., Okada, Y., Yoshida, Y., Kuroda, H., & Takikawa, Y. (2016) · Cytokine · doi:10.1016/j.cyto.2016.07.010 · Cited by 11
Biological therapies: concepts and challenges
Müller, M. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0670-6 · Cited by 11
Yun, J.-W., Kim, C.-W., Bae, I., Park, Y.-H., Chung, J., Lim, K., & Kang, K. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.09.017 · Cited by 11
Lee-Montiel, F. T., Laemmle, A., Dumont, L., Lee, C. S., Huebsch, N., Charwat, V., Okochi, H., HANCOCK, M. J., Siemons, B. A., Boggess, S. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.24.112771 · Cited by 11
Kadiyala, N. K., Mandal, B. K., Reddy, L. V. K., Barnes, C. H. W., Valladares, L. D. L. S., Maddinedi, S. B., & Sen, D. (2023) · ACS Omega · doi:10.1021/acsomega.3c02643 · Cited by 10
Drug-induced cholestasis: causative agents and challenges in diagnosis and management
Pinazo-Bandera, J. M., Toro-Ortiz, J. P., Andrade, R. J., & García‐Cortés, M. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00027 · Cited by 16
Targeting PKLR in liver diseases
Yuan, M., Shi, M., Yang, H., Ashraf, S., Iqbal, S., Türkez, H., Borén, J., Zhang, C., Uhlén, M., Altay, Ö., et al. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.009 · Cited by 12
The Sod2 mutant mouse as a model for oxidative stress: A functional proteomics perspective
Lee, Y. H., Lin, Q., Boelsterli, U. A., & Chung, M. C. M. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20226 · Cited by 12
Epigenetic Reprogramming of Human Hepatoma Cells: A Low-Cost Option for Drug Metabolism Assessment
Gailhouste, L., Liew, L. C., Yasukawa, K., Hagiwara, K., Iwazaki, N., Yamada, Y., Hatada, I., & Ochiya, T. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.006 · Cited by 11
Microfibrous Extracellular Matrix Changes the Liver Hepatocyte Energy Metabolism via Integrins
Huang, T., Jones, C. G., Chung, J. H., & Chen, C. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01311 · Cited by 10
Clinical Pathology in Nonclinical Toxicity Testing
Schultze, A. E., Ennulat, D., & Aulbach, A. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00017-0 · Cited by 10
Björnsson, H. K., & Bjornsson, E. S. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2288260 · Cited by 10
Synergistic protective effect of picrorhiza with honey in acetaminophen induced hepatic injury.
Gupta, P. K., Tripathi, A. S., Agrawal, T., Narayan, C., Singh, B. M., Kumar, M., & Kumar, A. (2016) · PubMed · Cited by 10
Zhu, Y., Shi, Q., Peng, Q., Gao, Y., Yang, T., Cheng, Y. Q., Wang, H., Luo, Y., Huang, A., He, T., et al. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4321 · Cited by 12
Yadav, A. S., Shah, N. R., Carlson, T. J., & Driscoll, J. P. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00268 · Cited by 10
The potential use of theranostic bacteria in cancer
Azizian, K., Pustokhina, I., Ghanavati, R., Hamblin, M. R., Amini, A., & Kouhsari, E. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30152 · Cited by 14
Advances in 3D cell culture for liver preclinical studies
Yao, T., Zhang, Y., Lv, M., Zang, G., Ng, S. S., & Chen, X. (2021) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmab046 · Cited by 11
Paracetamol and Simvastatin: A Potential Interaction Resulting in Hepatotoxicity
Gumbrevičius, G., Sveikata, A., Sveikatienė, R., & Stankevıčıus, E. (2012) · Medicina · doi:10.3390/medicina48070056 · Cited by 10
Klein, R. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0705-9 · Cited by 11
An Overview of Tissue Engineering as an Alternative for Toxicity Assessment
Garrod, M., & Chau, D. Y. S. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j35p6p · Cited by 11
Salwe, K. J., Ravichandran, M., Mano, J., & Manimekalai, K. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20172044 · Cited by 10
Cabb, E., Baltar, S., Powers, D. W., Mohan, K. R., Martinez, A., & Pitts, E. (2016) · Case Reports in Gastroenterology · doi:10.1159/000448883 · Cited by 10
Mendrick, D. L. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-048-9_1 · Cited by 10
Oniki, K., Ueda, K., Hori, M., Mihara, S., Marubayashi, T., & Nakagawa, K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100123 · Cited by 10
A guidance for renal biomarker lead optimization and use in translational pharmacodynamics
Ozer, J. S. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.12.001 · Cited by 9
Identification and Categorization of Liver Toxicity Markers Induced by a Related Pair of Drugs
Chang, C., Beland, F. A., Hines, W. M., Fuscoe, J. C., Han, T., & Chen, J. J. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12074609 · Cited by 9
Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
Boelsterli, U. A., & Kashimshetty, R. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01015-0 · Cited by 11
Morales, A. W., Zhang, Y. S., Aleman, J., Alerasool, P., Dokmeci, M. R., Khademhosseini, A., & Ye, J. Y. (2016) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2212971 · Cited by 10
A monkey model of acetaminophen-induced hepatotoxicity; phenotypic similarity to human
Tamai, S., Iguchi, T., Niino, N., Mikamoto, K., Sakurai, K., Sayama, A., Shimoda, H., Takasaki, W., & Mori, K. (2017) · The Journal of Toxicological Sciences · doi:10.2131/jts.42.73 · Cited by 9
Lesiński, W., Mnich, K., Golińska, A. K., & Rudnicki, W. R. (2021) · Biology Direct · doi:10.1186/s13062-020-00286-z · Cited by 11
Moore, R., Ashby, K., Liao, T.-J., & Chen, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010603 · Cited by 12
Oxidative Stress and Liver Injury
Cubero, F. J., & Trautwein, C. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_28 · Cited by 11
Watanabe, T., Abe, M., Tada, F., Aritomo, K., Ochi, H., Koizumi, Y., Tokumoto, Y., Hirooka, M., Kumagi, T., Ikeda, Y., et al. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3204 · Cited by 9
Mobasher, M. A., & Valverde, Á. M. (2014) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2014.893365 · Cited by 10
Moon, M. S., Kang, B.-H., Krzeminski, J., Amin, S., Aliaga, C. A., Zhu, J., McDevitt, E. I., Kocher, S., Richie, J. P., & Isom, H. C. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr231 · Cited by 9
Establishment of Animal Models of Drug-induced Liver Injury and Analysis of Possible Mechanisms
Oda, S., & Yokoi, T. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00249-2 · Cited by 9
Mizuno, K., Takeuchi, K., Umehara, K., & Nakajima, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.043 · Cited by 9
Villanueva-Bádenas, E., Donato, M. T., & Tolosa, L. (2023) · Antioxidants · doi:10.3390/antiox12071315 · Cited by 9
Abdellaoui-Soussi, F. E., Brusilovsky, M., Buck, E., Bacon, W. C., Dadgar, S., Fullerton, A. M., Durban, V. M., Barrile, R., Helmrath, M. A., Takebe, T., et al. (2025) · Advanced Science · doi:10.1002/advs.202508584 · Cited by 16
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury
Roth, R. A., Kana, O. Z., Filipovic, D., & Ganey, P. E. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2113379 · Cited by 9
Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study
Hu, T., Sun, Y., & An, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.994821 · Cited by 9
Yang, X., Zhan, Y., Sun, Q., Xu, X., Kong, Y., & Zhang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.14059 · Cited by 8
Hosogi, J., Ohashi, R., Maeda, H. A., Fujita, K., Ushiki, J., Kuwabara, T., Yamamoto, Y., & Imamura, T. (2018) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2123 · Cited by 8
Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator
Rennie, G. R., Barden, T. C., Bernier, S. G., Carvalho, A., Deming, R., Germano, P., Hudson, C., Im, G.-Y. J., Iyengar, R. R., Jia, L., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127886 · Cited by 9
Current Models for Predicting Drug-induced Cholestasis: The Role of Hepatobiliary Transport System.
Jazaeri, F., Sheibani, M., Nezamoleslami, S., Moezi, L., & Dehpour, A. R. (2021) · PubMed Central · doi:10.22037/ijpr.2020.113362.14254 · Cited by 10
Age-Associated Risk of Liver-Related Adverse Drug Reactions
Han, Y., Guo, Y.-M., Xiong, P., Ge, F., Jing, J., Niu, M., Zhao, X., Bai, Z., Song, H., Xiao, X., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.832557 · Cited by 8
Yun, J.-W., Kim, M., Cho, S. D., Lee, J. Y., Bae, O., & Lim, K. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.06.010 · Cited by 8
Genetic variants of hepatic transporters and susceptibility to drug induced liver injury
Bhatnagar, P., Day, C., Aithal, G. P., Pirmohamed, M., Bernal, W. E., & Daly, A. K. (2008) · Toxicology · doi:10.1016/j.tox.2008.07.008 · Cited by 8
Protective Effects of Calpurnia aurea Seed Extract on HAART Hepatotoxicity
Mulata, H., Seifu, D., Umeta, M., Ergete, W., & Gnanasekaran, N. (2015) · European Journal of Medicinal Plants · doi:10.9734/ejmp/2015/17677 · Cited by 8
Ji, D. C. (2017) · Journal of Drug Abuse · doi:10.21767/2471-853x.100054 · Cited by 9
Early Biomarkers for Severe Drug Hypersensitivity Reactions
Ariza, A., Torres, M. J., Moreno, C., Fernández‐Santamaría, R., & Fernández, T. D. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191107105440 · Cited by 8
Du, H., Zhao, S., Zhao, W. T., Fu, N., Li, W., Qin, X.-J., Zhang, Y., Nan, Y., & Zhao, J. (2021) · PubMed · doi:10.14670/hh-18-340 · Cited by 14
Microfluidic devices for drug discovery and analysis
Kochhar, J. S., Chan, S. Y., Ong, P.-S., Lee, W. G., & Kang, L. (2013) · Elsevier eBooks · doi:10.1533/9780857097040.2.231 · Cited by 11
Ware, B. R., Brown, G. E., Soldatow, V. Y., LeCluyse, E. L., & Khetani, S. R. (2019) · Gene Expression · doi:10.3727/105221619x15638857793317 · Cited by 9
Morphologische Veränderungen der medikamenteninduzierten Leberschädigung
Kasper, H., Drebber, U., Hirsch, I., & Dienes, H. P. (2006) · Der Pathologe · doi:10.1007/s00292-006-0826-1 · Cited by 8
Okada, R., Ishizu, Y., Endo, R., Lezhava, A., Ieiri, I., Kusuhara, H., Sugiyama, Y., & Hayashizaki, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034652 · Cited by 8
The Importance of Applying Toxicogenomics to Increase the Efficiency of Drug Discovery
Barros, S. A. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.6.547 · Cited by 8
Kenna, J. G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1290082 · Cited by 7
Hepatotoxicity due to dietary supplements: state-of-the-art, gaps and perspectives
Rivero‐Pino, F., & Casanova, A. G. (2023) · Critical Reviews in Toxicology · doi:10.1080/10408444.2023.2282415 · Cited by 8
In vitro liver models for toxicological research
Fukunaga, I., & Takebe, T. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2025.101478 · Cited by 7
Toyoda, Y., Kashikura, K., Soga, T., & Tagawa, Y. (2017) · The Journal of Toxicological Sciences · doi:10.2131/jts.42.445 · Cited by 9
Gawlik, M., & Skibiński, R. (2018) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2018.08.008 · Cited by 7
Comparison of in vitro models for drug-induced liver injury assessment
Kim, N., Bang, J., Yi, H., Ku, H., Kim, J., Kim, J.-Y., & Jeon, B.-S. (2024) · Journal of Biomedical Translational Research · doi:10.12729/jbtr.2024.25.2.53 · Cited by 8
Yun, J.-W., Lee, T. R., Kim, C.-W., Park, Y.-H., Chung, J., Lee, Y.-S., Kang, K., & Lim, K. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq037 · Cited by 7
Béquignon, O. J. M., Pawar, G. V., van de Water, B., Cronin, M., & van Westen, G. J. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11535-1 · Cited by 10
Wei, J., Lei, D., Chen, M., Ran, P., & Li, X. (2020) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34669 · Cited by 8
Recent Progress in Prediction Systems for Drug-induced Liver Injury Using In vitro Cell Culture
Ozawa, S., Miura, T., Terashima, J., Habano, W., & Ishida, S. (2020) · Drug Metabolism Letters · doi:10.2174/1872312814666201202112610 · Cited by 8
Prediction of drug-induced hepatotoxicity based on histopathological whole slide images
Su, R., He, H., Sun, C., Wang, X., & Liu, X. (2023) · Methods · doi:10.1016/j.ymeth.2023.01.005 · Cited by 8
Metadata
- Authors
- Kaplowitz, N.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Kaplowitz, Neil
- ORCID
- Kaplowitz, Neil
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-06
- Volume
- 4
- Issue
- 6
- Pages
- 489-499
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2017783406
- Cited by
- 1,054
- References
- 155
- Citations by year
- 2026: 29 · 2025: 35 · 2024: 35 · 2023: 44 · 2022: 31 · 2021: 49 · 2020: 45 · 2019: 48 · 2018: 54 · 2017: 66 · 2016: 72 · 2015: 55 · 2014: 64 · 2013: 57 · 2012: 52
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, troglitazone, preclinical toxicology, hepatotoxicity prediction, pharmacovigilance, acetaminophen hepatotoxicity, innate immune system, cell death pathways, drug withdrawal, post-marketing surveillance
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Liver, Liver Diseases, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.